TARIS Biomedical, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Lexington MA United States (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2010
NCT01150565
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Taris Biomedical LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

lidocaine (xylocaine) (4 trials)

Drugs in Phase 1 Trials (2)

gemcitabine (gemzar) (3 trials)

nivolumab (opdivo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cystitis (Phase 2)

Cystitis, Interstitial (Phase 2)

Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 3